Kaul S, Srinivas N R, Mummaneni V, Igwemezie L N, Barbhaiya R H
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA.
Semin Oncol. 1996 Dec;23(6 Suppl 13):23-9.
The influence of gender, age, and race on the pharmacokinetics of etoposide and on the extent of conversion of etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) to etoposide are summarized. Included in the integrated statistical analyses were 192 patients from six phase I/II studies (102 men and 90 women, 128 aged < or = 65 years and 64 aged > 65 years; 134 were white, 18 were other races, and race was not recorded for 40). The dose of etoposide phosphate ranged from 25 to 200 mg/m2 of etoposide equivalents and was administered as 5-(bolus) to 210-minute intravenous infusions. Total body clearance of etoposide was comparable between men and women. However, significantly lower steady-state volumes of distribution and shorter half-lives were observed in women relative to men. Patients who were older than 65 years had significantly lower etoposide total body clearance and longer half-lives than younger patients. The gender- and age-related differences observed in the pharmacokinetic parameters of etoposide were significant but generally of a small magnitude (< or = 13%), indicating no need for dose adjustment in these patient populations. There were no significant race-related differences in the pharmacokinetic parameters of etoposide. All patients showed rapid conversion of etoposide phosphate to etoposide. The individual area under the plasma concentration-time curve ratio of etoposide phosphate/etoposide was < or = 0.0324, indicating that etoposide was the major circulating moiety after infusion of etoposide phosphate. Significant gender-, age-, or race-related differences in the area under the plasma concentration-time curve ratios were not observed. An evaluation of the area under the plasma concentration-time curve ratios with respect to infusion time suggested that the conversion of etoposide phosphate to etoposide was independent of infusion time.
总结了性别、年龄和种族对依托泊苷药代动力学以及依托泊苷磷酸酯(依托泊苷磷酸酯;百时美施贵宝公司,新泽西州普林斯顿)转化为依托泊苷程度的影响。纳入综合统计分析的有来自六项I/II期研究的192名患者(102名男性和90名女性,128名年龄≤65岁,64名年龄>65岁;134名是白人,18名是其他种族,40名未记录种族)。依托泊苷磷酸酯的剂量范围为25至200mg/m²依托泊苷当量,给药方式为5分钟(推注)至210分钟静脉输注。依托泊苷的总体清除率在男性和女性之间相当。然而,与男性相比,女性的稳态分布容积显著更低,半衰期更短。65岁以上的患者比年轻患者的依托泊苷总体清除率显著更低,半衰期更长。在依托泊苷药代动力学参数中观察到的性别和年龄相关差异具有显著性,但一般幅度较小(≤13%),表明在这些患者群体中无需调整剂量。依托泊苷的药代动力学参数没有显著的种族相关差异。所有患者均显示依托泊苷磷酸酯迅速转化为依托泊苷。依托泊苷磷酸酯/依托泊苷的血浆浓度-时间曲线下个体面积比≤0.0324,表明依托泊苷磷酸酯输注后依托泊苷是主要的循环部分。未观察到血浆浓度-时间曲线下面积比存在显著的性别、年龄或种族相关差异。对血浆浓度-时间曲线下面积比相对于输注时间的评估表明,依托泊苷磷酸酯向依托泊苷的转化与输注时间无关。